Homocysteine lowering with folic acid and B vitamins in vascular disease.

Study answer

What this study found

The combination lowered homocysteine but did not reduce major vascular events overall. The primary outcome occurred in 519 participants (18.8%) in the active group versus 547 (19.8%) with placebo (relative risk 0.95; 95% CI 0.84 to 1.07; P = 0.41). Mean total plasma homocysteine fell from 12.2 to 9.7 μmol per liter in the active group, while it rose from 12.2 to 12.9 μmol per liter with placebo; the between-group difference in change was 3.2 μmol per liter at the end of the study. Stroke was reduced (111 [4.0%] vs 147 [5.3%]; RR 0.75; 95% CI 0.59 to 0.97; P = 0.03), but death from any cause…

Study & population

Randomized, placebo-controlled, multicenter trial in adults aged 55 years or older with a history of vascular disease or diabetes plus additional atherosclerotic risk factors.

Intervention

The active regimen was a daily oral combined pill containing folic acid 2.5 mg, vitamin B6 50 mg, and vitamin B12 1 mg, given for a mean follow-up of 5 years and compared with matching placebo.

Key limitation

The primary vascular outcome was negative despite clear biochemical homocysteine lowering, so the clinical benefit was limited.

View full study detailsView sourceOpen PDF

Original abstract